Edition:
United States

Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

6.40USD
25 Apr 2018
Change (% chg)

$-0.25 (-3.76%)
Prev Close
$6.65
Open
$6.60
Day's High
$6.60
Day's Low
$6.30
Volume
6,783
Avg. Vol
15,846
52-wk High
$13.30
52-wk Low
$4.10

Select another date:

Tue, Apr 10 2018

BRIEF-Trillium Therapeutics Provides Update On Its Clinical Programs

* TRILLIUM THERAPEUTICS PROVIDES UPDATE ON ITS TTI-621 AND TTI-622 CLINICAL PROGRAMS

BRIEF-Trillium Therapeutics' TTI-621 Receives Orphan Drug Designation For Treatment Of Cutaneous T-Cell Lymphoma

* TRILLIUM THERAPEUTICS' TTI-621 RECEIVES ORPHAN DRUG DESIGNATION FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA Source text for Eikon: Further company coverage:

BRIEF-Trillium Therapeutics Reports Annual 2017 Financial And Operating Results

* TRILLIUM THERAPEUTICS REPORTS ANNUAL 2017 FINANCIAL AND OPERATING RESULTS

BRIEF-Trillium Therapeutics Inc Files For Mixed Shelf Of Upto $150 Mln

* TRILLIUM THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text : http://bit.ly/2jZxGi0 Further company coverage:

BRIEF-Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics

* MATRIX CAPITAL MANAGEMENT COMPANY LP REPORTS A 16.5 PCT PASSIVE STAKE IN TRILLIUM THERAPEUTICS INC AS OF NOV 30 - SEC FILING Source text: (http://bit.ly/2yOHuTW) Further company coverage:

BRIEF-Trillium announces private placement to fund development of cancer drugs

* Trillium Therapeutics - ‍entered into subscription agreements for sale of 1.95 million shares & 400,000 Series II non-voting convertible first preferred shares​

BRIEF-Trillium Therapeutics reports Q3 results

* Trillium Therapeutics reports third quarter 2017 financial and operating results

Select another date: